Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Mucosal Vaccines: Advances in Technology and Delivery
share announcement

Mucosal Vaccines: Advances in Technology and Delivery

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 1909

Special Issue Editors

Prof. Dr. Kai Zhao

E-Mail Website
Guest Editor
Institute of Nanobiomaterials and Immunology, Advanced Research Institute, School of Life Science, Taizhou University, Taizhou 318000, China
Interests: vaccine; adjuvanted vanncine; microspheres/nanoparticle; vaccine delivery system; intranasal delivery; mucosal immunity
Special Issues, Collections and Topics in MDPI journals
Dr. Shangen Xu

E-Mail Website
Guest Editor Assistant
School of Life Science, Taizhou University, Taizhou 318000, China
Interests: adjuvant
Dr. Yuhong Lin

E-Mail Website
Guest Editor Assistant
Institute of Nanobiomaterials and Immunology, Advanced Research Institute, School of Life Science, Taizhou University, Taizhou 318000, China
Interests: adjuvant

Special Issue Information

Dear Colleagues,

Mucosal vaccines are an attractive immunization platform with long-term local immune response and improved immunogenicity. As mucosal surfaces serve as the initial contact points for numerous pathogens, they present a unique avenue for immunological engagement. Mucosal vaccines can induce mucosal immune responses, preventing infectious pathogens from attaching and colonizing mucosal epithelia and stopping invasive bacteria and viruses from penetrating and replicating within the mucosa. Mucosal vaccines have several advantages, including their non-invasive nature and not requiring injections, which reduces physical and psychological discomfort for patients, increases patients’ willingness to accept the vaccine, and improves safety.

This Special Issue focuses on presenting an exhaustive synopsis of the latest technological progress and delivery methodologies that augment mucosal vaccines' potency and safety profiles. By highlighting groundbreaking research—encompassing novel vaccines and adjuvants, delivery platforms, and immune-stimulating formulations—this Special Issue endeavors to deepen the comprehension of mucosal immune mechanisms and further novel developments in vaccine delivery systems for mucosal immunization.

Prof. Dr. Kai Zhao
Guest Editor

Dr. Shangen Xu
Dr. Yuhong Lin
Guest Editor Assistants

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mucosal immunization
  • mucosal vaccine
  • adjuvant
  • vaccine delivery strategy
  • vaccine formulations
  • immune response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 12041 KB  
Article
Novel Intranasal Replication-Deficient NS1ΔC Flu Vaccine Confers Protection from Divergent Influenza A and B Viruses in Mice
by Daria Shamakova, Marina A. Shuklina, Nikita Yolshin, Ekaterina Romanovskaya-Romanko, Anna-Polina Shurygina, Kira Kudrya, Arman Muzhikyan, Mariia V. Sergeeva and Marina Stukova
Vaccines 2026, 14(1), 43; https://doi.org/10.3390/vaccines14010043 - 30 Dec 2025
Viewed by 1059
Abstract
Background/Objectives: The current strategy for seasonal influenza prophylaxis relies on updating the vaccine components annually to account for the rapid antigenic drift of viruses and the low cross-protective efficacy of available vaccines. Mutant influenza viruses with truncated or deleted NS1 protein are [...] Read more.
Background/Objectives: The current strategy for seasonal influenza prophylaxis relies on updating the vaccine components annually to account for the rapid antigenic drift of viruses and the low cross-protective efficacy of available vaccines. Mutant influenza viruses with truncated or deleted NS1 protein are known to stimulate cross-specific T-cell immune response and provide protection against heterosubtypic influenza A and B viruses. Methods: We generated NS1ΔC influenza A and B viruses with C-terminal NS1 deletions by reverse genetics. In a mouse model, we assessed the safety and immunogenicity of the B/Lee/NS1ΔC strain upon intranasal administration, as well as the mechanism of its cross-protective efficacy against sublethal B/Victoria and B/Yamagata challenges. We then investigated the potential of the intranasal Flu/NS1ΔC vaccine–a trivalent formulation of NS1ΔC A/H1N1, A/H3N2, and B influenza viruses–to protect mice from lethal influenza infection with homologous, heterologous, and antigenically drifted influenza A and B viruses. Results: Intranasal immunization with the B/Lee/NS1ΔC strain was safe in mice. It activated cross-specific T-cell responses in the lungs and protected animals against heterologous challenge by reducing viral load, inflammation, and lung pathology. Immunization with the trivalent Flu/NS1ΔC vaccine formulation improved survival and reduced weight loss and viral load upon challenge with A/H1N1pdm, A/H2N2, A/H5N1, and B/Victoria viruses. Conclusions: The trivalent intranasal Flu/NS1ΔC influenza vaccine is a promising tool to improve seasonal influenza protection and preparedness for an influenza pandemic. Full article
(This article belongs to the Special Issue Mucosal Vaccines: Advances in Technology and Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop